Comparing treatments for AML that returns or doesn't respond
Part of Blood & lymphatic, Cancer clinical trials.
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- Your AML must be either 'primary refractory' (did not respond to first treatment) or 'early relapsed' (came back within about 6–12 months).
- You cannot have had a stem cell transplant before.
- You cannot have taken venetoclax and had it stop working.
- You must not be pregnant or breastfeeding.
- You cannot have another active cancer that was treated in the last 3 years (except some skin or early-stage cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
This trial compares two types of chemotherapy for people with acute myeloid leukemia (AML) that came back or did not get better after initial treatment. Your doctor will help decide if you can join, and you will be randomly assigned to either a lower-intensity or a higher-intensity treatment plan.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
This trial uses a special lab test (pharmacoscopy) to help your doctor choose the best standard chemotherapy for your AML. It is for people whose leukemia has returned or not responded to treatment, and who are strong enough for intensive chemotherapy.
Hear when a new Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.